Strategy and governance

Our strategic priorities 

We aim to achieve our vision of reducing the global burden of pulmonary vascular disease (PVD) through Advocacy, Collaboration, and Education.  
 

  1. We advocate for PVD to be well understood and properly resourced 
    To make this happen we provide practical support to regional PH groups working to improve local diagnosis and care, and we advocate for better core standards in diagnosis and treatment, and to end inequalities in PVD healthcare. Our Regional Task Forces are key to this work. 
     
  2. We collaborate globally to share knowledge and inspire cutting-edge research
    We bring together the best PVD professionals in the world - clinicians,  academics, scientists and industry leaders -  to increase our collective knowledge. We provide open, inclusive platforms for them to collaborate on cutting-edge basic, clinical, and translational research to achieve results that no single individual or academic institution could accomplish alone.  

    Through our IDDI Workstreams, we facilitate the development of diagnostics, treatments and therapies that improve life expectancy and quality of life whilst generating a significant sustainable income stream. 

    Through our Specialty Task Forces, we bring together clinicians, researchers, and academia to develop innovative solutions to the key problems facing the PH community. 
     
  3. We educate healthcare professionals to improve diagnosis, treatment, and care 
    We deliver high-quality conferences and online learning., and we make sure these are accessible, open and welcoming to all. We feature the latest in cutting-edge PH research from globally renowned specialists, and provide opportunities for networking with an increasing focus on supporting early-career professionals and those from low-income countries.

    We are also taking steps to position our academic journal, Pulmonary Circulation, as the go-to publication for high-quality, cutting-edge PH research. In line with our commitment to equitable global PH education, the journal is fully open access. 

 

We are also building strong foundations for our future...

We ensure that PVRI has a clear vision and strategic direction and that our leadership is equipped to deliver on our ambitions.  We work hard to make our finances, policies, people and systems effective and efficient, so that we can continue to support our global network for years to come. 

...and we are committed to diversity, equity and inclusion:

  • we work hard to ensure that our global network has a diverse and inclusive leadership
  • we cultivate an inclusive community where difference is celebrated, everyone feels respected and able to contribute to their full potential
  • we strive to communicate inclusively
  • we work to gain a better understanding of the global burden of PH as it affects different people and communities. With an improved understanding, we’ll be better placed to help our global PH community to tackle PH health inequalities

In 2006, a group of visionary researchers and medical professionals (Ghazwan Butrous, Stuart Rich, Martin Wilkins, Nick Morrell, Evangelos Michelakis, Marc Semigran and Fritz Grimminger) came together at Heathrow Airport in London, UK, to share their expertise and discuss ways to combat PVD. At that meeting, the Pulmonary Vascular Research Institute (PVRI) was born. 

The following year, Task Forces were established, a Board of Directors and Trustees were appointed, we gained charitable status in the UK and the USA, and our first Annual Congress was held in Malta. 

Collaboration was central to our approach from the beginning, and our influence quickly grew as experts from across the world joined us. In 2008, Dr Chen Wang established a PVRI China Centre at Beijing Hospital. In the same year, our Annual Congress was held in Marbella, Spain, and our first webinars allowed researchers and medical professionals to exchange knowledge and expertise globally. 

In 2009, we held our third Annual Congress in Mexico, which generated high-level scientific debate and discussion. Social events like the PVRI gathering at the American Thoracic Society meeting in San Diego soon followed. 

The PVRI Review, our non-peer-reviewed publication, began to shape Pulmonary Vascular Disease (PVD) thought leadership. In 2011, our Paediatric Task Force introduced the functional classification of pulmonary hypertension and PVD stages in children, elevating care standards for young patients. In the same year, we published the first issue of our quarterly peer-reviewed medical journal, Pulmonary Circulation, which was indexed in PubMed after only two issues. 

Between 2011 and 2014, Annual Congresses were held in Portugal (2010), Panama (2011), South Africa (2012), Turkey (2013), and Germany (2014). In 2014, our first annual Drug Discovery and Development Symposium was held in Bethesda, USA with 100 attendees, and by 2015, our ninth Annual Congress was held in China. 

Between 2016 and 2018, Annual Congresses were held in Italy, Miami and Singapore. In 2018, we increased industry participation in our roundtable, with 11 participating pharmaceutical companies. We awarded over 37 educational grants to our members (worth over £50,000) and published over 100 articles in Pulmonary Circulation. 

Since then, our Annual Congresses have been held in Spain, Peru, and Greece, and in 2024, they made it full circle back to London, UK. In 2024, we held our largest Congress in London with over 500 attendees from 33 countries.

Our work continues to touch countless lives and bring us all one step closer to our ultimate goal — a world free from PVD.

Watch Our History video

Find out more...

About us
What we do
Our corporate partnerships
Strategy and governance
Our people
PVRI Careers and opportunities
Contact us
Brad speaking PVRI 2026 Dublin
Our values

Our values

We are open
We promote transparency, open scientific exchange and free sharing of ideas and knowledge across the globe pulmonary vascular community

We are inclusive
We are committed to bringing together expertise from underrepresented groups, including low- and middle-income countries (LMIC), women and early career professionals

We are easy to engage with
We are approachable and collaborative, making it straightforward for our members, partners and wider community to participate in our initiatives, groups and events

We are ambitious
We are ambitious for ourselves and our wider community to see meaningful progress in pulmonary vascular treatment and care

Our structure, governance and finances

  1. Audited Accounts for 2024
  2. Audited Accounts for 2023
  3. Audited Accounts for 2022
  4. Diversity, Equity & Inclusion Policy
  5. Ethical Sponsorship, Fundraising & Partnership Policy
  6. Our Supporter Promise
  7. PVRI Constitution